Synapse - Genitourinary Oncology Service

Results (41)

A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes

Journal Article

Autio, K. A.; Kyriakopoulos, C. E.; Palyca, P.; Xiao, H.; Emamekhoo, H.; Danila, D.; Jan, M.; Catharine, V.; Riedel, E.; Devitt, M.; more...
Investigational New Drugs (2025)

Fulltext@MSK | Save

A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors

Journal Article

Adra, N.; Vaughn, D. J.; Einhorn, L. H.; Hanna, N. H.; Funt, S. A.; Rosales, M.; Arozullah, A.; Feldman, D. R.
Investigational New Drugs (2022)

Fulltext@MSK | Save

Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors

Journal Article

Ashkar, R.; Feldman, D. R.; Adra, N.; Zaid, M. A.; Funt, S. A.; Althouse, S. K.; Perkins, S. M.; Snow, C. I.; Lazzara, K. M.; Sego, L. M.; more...
Investigational New Drugs (2021)

Fulltext@MSK | Save

Characterization and management of ERK inhibitor associated dermatologic adverse events: Analysis from a nonrandomized trial of ulixertinib for advanced cancers

Journal Article

Wu, J.; Liu, D.; Offin, M.; Lezcano, C.; Torrisi, J. M.; Brownstein, S.; Hyman, D. M.; Gounder, M. M.; Abida, W.; Drilon, A.; more...
Investigational New Drugs (2021)

Fulltext@MSK | Save

Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer

Journal Article

Gartrell, B. A.; Roach, M. 3rd; Retter, A.; Sokol, G. H.; Del Priore, G.; Scher, H. I.
Investigational New Drugs (2021)

Fulltext@MSK | Save

Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)

Journal Article

Hecht, J. R.; Papadopoulos, K. P.; Falchook, G. S.; Patel, M. R.; Infante, J. R.; Aljumaily, R.; Wong, D. J.; Autio, K. A.; Wainberg, Z. A.; Bauer, T. M.; more...
Investigational New Drugs (2021)

Fulltext@MSK | Save

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer

Journal Article

McHugh, D.; Eisenberger, M.; Heath, E. I.; Bruce, J.; Danila, D. C.; Rathkopf, D. E.; Feldman, J.; Slovin, S. F.; Anand, B.; Chu, R.; more...
Investigational New Drugs (2019)

Fulltext@MSK | Save

A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer

Journal Article

Graham, L.; Banda, K.; Torres, A.; Carver, B. S.; Chen, Y.; Pisano, K.; Shelkey, G.; Curley, T.; Scher, H. I.; Lotan, T. L.; more...
Investigational New Drugs (2018)

Fulltext@MSK | Save

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel

Journal Article

Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
Investigational New Drugs (2017)

Fulltext@MSK | Save

Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer

Journal Article

Hussain, M.; Carducci, M. A.; Slovin, S.; Cetnar, J.; Qian, J.; McKeegan, E. M.; Refici-Buhr, M.; Chyla, B.; Shepherd, S. P.; Giranda, V. L.; more...
Investigational New Drugs (2014)

Fulltext@MSK | Save